Clinical trials

5

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health

A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health.

Participants needed: 112
Trial details
Phase: Phase 1Age: 18-50Biological sex: AllType: InterventionalSponsor: International AIDS Vaccine InitiativeUpdated: Jun 18, 2026Locations: 3
Eligibility criteria

Adults in good general health [+8]

Any clinically significant acute or chronic medical condition that is considered... [+15]

Status: Recruiting

A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health

A Phase 1 Randomized, Observer Blind, Placebo-controlled, Dose-escalation and dose expansion Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health

Participants needed: 112
Trial details
Phase: Phase 1Age: 18-50Biological sex: AllType: InterventionalSponsor: International AIDS Vaccine InitiativeUpdated: Apr 15, 2026Locations: 2
Eligibility criteria

Adults in good general health [+7]

Any clinically significant acute or chronic medical condition that is considered... [+15]

Status: Recruiting

A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic Region.

A Phase 2b, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of a candidate tuberculosis (TB) vaccine, MTBVAC, against TB disease in adolescents and adults aged 14-45 years, living in a TB endemic region.

Participants needed: 5,500
Trial details
Phase: Phase 2Age: 14-45Biological sex: AllType: InterventionalSponsor: International AIDS Vaccine InitiativeUpdated: Mar 31, 2026Locations: 16
Eligibility criteria

Is male or female aged 14 through 45 years on Study Day 1. [+13]

Acute illness and/or axillary temperature ≥37.5°C on Study Day 1. [+14]

Status: Recruiting

A Trial of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine, Administered to Healthy Adults Living Without and With HIV.

A Phase 1 Randomized Double Blinded Placebo Controlled, Dose Ranging Trial, of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine (GRAdHIVNE1 Vaccine), Administered to Healthy Adults Living without HIV and Living with HIV, in Southern Africa

Participants needed: 120
Trial details
Phase: Phase 1Age: 18-50Biological sex: AllType: InterventionalSponsor: International AIDS Vaccine InitiativeUpdated: Feb 13, 2026Locations: 3
Eligibility criteria

At least 18 years of age on the day of screening and has not reached his or her... [+12]

Any clinically significant acute or chronic medical condition, other than HIV in... [+3]

Status: Recruiting

A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa

A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults and Children Residing in West Africa

Participants needed: 612
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: International AIDS Vaccine InitiativeUpdated: May 11, 2025Locations: 3
Eligibility criteria

Adults, adolescents, and children in good general health as assessed by medical... [+21]

Confirmed HIV-1 or HIV-2 infection (except as outlined for Group 2) [+40]